Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort

Lorelei A. Mucci*, Yudi Pawitan, Francesca Demichelis, Katja Fall, Jennifer R. Stark, Hans Olov Adami, Swen Olof Andersson, Ove Andrén, Anna S. Eisenstein, Lars Holmberg, Wei Huang, Philip W. Kantoff, Sven Perner, Meir J. Stampfer, Jan Erik Johansson, Mark A. Rubin

*Corresponding author for this work
8 Citations (Scopus)

Abstract

Tumor molecular markers hold promise to distinguish potentially lethal from indolent prostate cancer and to guide treatment choices. A previous study identified a nine-gene molecular signature in tumors associated with prostate-specific antigen relapse after prostatectomy. We examined this molecular model in relation to prostate cancer death among 172 men with initially localized disease. We quantified protein expression of the nine genes in tumors to classify progression risk. Accounting for clinical prognostic factors, the nine-gene model did not provide discrimination to predict lethal and indolent prostate cancer.

Original languageEnglish
JournalCancer Epidemiology Biomarkers and Prevention
Volume17
Issue number1
Pages (from-to)249-251
Number of pages3
ISSN1055-9965
DOIs
Publication statusPublished - 01.01.2008

Fingerprint

Dive into the research topics of 'Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort'. Together they form a unique fingerprint.

Cite this